[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100355230":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":52,"collaborators":54,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":18,"enrollmentInfo":96,"targetDuration":18,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Centre Hospitalier Universitaire, Amiens","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"algorithm arm","EXPERIMENTAL","Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.",[13],"Diagnostic Test: algorithm",{"label":15,"type":16,"description":17,"interventionNames":18},"no algorithm arm","NO_INTERVENTION","Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DIAGNOSTIC_TEST","algorithm","clinical examination and procalcitonin assessment",[9],[26],{"name":27,"affiliation":28,"role":29},"Jean-Marc Regimbeau, Pr","CHU Amiens","PRINCIPAL_INVESTIGATOR",[31],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},"CONTACT","(33) 322 088 897","regimbeau.jean-marc@chu-amiens.fr",[36],{"facility":37,"status":38,"city":39,"state":18,"zip":18,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Amiens Universitary Hospital","RECRUITING","Amiens","France","FR",{"type":43,"coordinates":44},"Point",[45,46],2.3,49.9,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":51,"phoneExt":18,"email":34},"jean marc Regimbeau, MD, PhD","+33 3 22 08 89 05",{"type":53,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[55,57,59,61,63,65,67,69,71,73,75,77,79,81,83],{"name":56,"class":6},"Centre Hospitalier de Beauvais",{"name":58,"class":6},"University Hospital, Rouen",{"name":60,"class":6},"University Hospital, Caen",{"name":62,"class":6},"University Hospital, Lille",{"name":64,"class":6},"Groupe Hospitalier Pitie-Salpetriere",{"name":66,"class":6},"Centre Hospitalier Universitaire Dijon",{"name":68,"class":6},"University Hospital, Limoges",{"name":70,"class":6},"Saint Antoine University Hospital",{"name":72,"class":6},"University Hospital, Clermont-Ferrand",{"name":74,"class":6},"Hôpital Cochin",{"name":76,"class":6},"University Hospital, Toulouse",{"name":78,"class":6},"Centre Hospitalier de PAU",{"name":80,"class":6},"Hopital Lariboisière",{"name":82,"class":6},"Tourcoing Hospital",{"name":84,"class":85},"Central Hospital Saint Quentin","OTHER_GOV","100355230","a-procalcitonin-based-algorithm-in-adhesion-related-small-bowel-obstruction-100355230",false,"NCT03905239","A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction","Impact of a Procalcitonin-based Algorithm on Quality of Management in Patients With Uncomplicated Adhesion-related Small Bowel Obstruction Assessed by Textbook Outcome: a Multicenter Cluster-randomized Open-label Controlled Trial. (ALPROC)","ALPROC","Inclusion Criteria:\n\n* Uncomplicated acute adhesion-related small bowel obstruction (ASBO)\n* Adults\n* Patients able to express consent\n* Signed written informed consent form\n* Covered by national health insurance\n\nExclusion Criteria:\n\n* Disease-related criteria:\n* Large bowel obstruction\n* No previous abdominal surgery\n* Signs of peritonitis or strangulation requiring emergency surgery)\n* Obstruction within 4 weeks following previous surgery\n* Ongoing or history of bowel cancer\n* Ongoing or in history of inflammatory bowel disease\n* History of abdominal radiotherapy\n* Active infection\n* Contraindication to contrast-enhanced CT scan\n* Minors\n* Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":97,"type":98},488,"ESTIMATED","INTERVENTIONAL",[101],"NA","Adhesion-related small bowel obstruction is a common digestive emergency that can be managed either conservatively or surgically. However, the choice between these two approaches can be difficult due to the absence of specific signs. The objective of this study is to evaluate the clinical impact of a procalcitonin-based algorithm.",[104],"Small Bowel Obstruction",[22,106,107],"procalcitonin","small bowel obstruction","2025-06-05",{"date":110,"type":111},"2025-06-08","ACTUAL",{"date":113,"type":111},"2019-04-01",{"date":115,"type":98},"2026-08-01",{"name":5,"class":6},1]